- Doctors | Friday, June 06.
- Doctors | Saturday, June 07.
- Nurses | Saturday, June 07.
| 11:55 – 12:00 | Marko Jakopović Welcome |
| Diagnostics and staging of lung cancer Chairpersons: Kristina Krpina, Marta Koršić | |
| 12:00 – 12:15 | Kristina Krpina Results from National lung cancer screening program and future targets |
| 12:15 – 12:30 | Lela Bitar Staging classification: Differences of c, p, y, r and a TNM classification – what should be written and when and why? |
| 12:30 – 12:45 | Sonja Badovinac Impact of the new TNM Classification on EBUS for Lung Cancer Staging |
| 12:45 – 13:00 | Marta Koršić The role of thoracoscopy in diagnosis of thoracic malignancies |
| 13:00 – 13:15 | Bojan Zarić The role of ctDNA in NSCLC – early and advanced disease |
| Locally advanced lung cancer Chairpersons: Marko Jakopović, Lela Bitar | |
| 13:15 – 13:30 | Suzana Mladinov Treatment of unresectable stage III NSCLC – state of the art |
| 13:30 – 13:45 | Mir Ali Reza Hoda The role of surgery in stage III NSCLC |
| 13:45 – 14:00 | Jasna But Hadžić SBRT in central tumors |
| 14:00 – 14:30 | Satellite symposium BMS Nivolumab and Ipilimumab in Treatment of Thoracic Malignancies Dražena Srdić First-line nivolumab plus ipilimumab in patients with unresectable MPM, Case report Ivana Canjko CheckMate 9LA, First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer, Case report |
| 14:30 – 15:00 | Coffee break |
| 15:00 – 15:30 | Satellite symposium AstraZeneca Maximilian Johannes Hochmair Contemporary treatment of EGFRm metastatic non-small cell lung cancer – FLAURA 2 |
| Early-stage lung cancer Chairpersons: Mir Ali Reza Hoda, Bojan Zarić | |
| 15:30 – 15:45 | Davorin Radosavljević Peri-operative treatment in patients with molecular alterations |
| 15:45 – 16:15 | Maximilian Johannes Hochmair Peri-operative immunotherapy – importance of pCR and MPR |
| 16:15 – 16:30 | Marijo Boban SBRT in early-stage lung cancer – is it worth it? |
| Special considerations Chairpersons: Marko Jakopović, Sanja Pleština | |
| 16:30 – 16:45 | Luka Brčić Do we need to do molecular analysis of every subtype of lung cancer and why? |
| 16:45 – 17:00 | Latinka Basara Approach to lung cancer patient – psychologist point of view |
| 17:00 – 17:15 | Tomi Kovačević Spirituality as vital aspects of palliative care in patients with LC |
| 17:15 – 17:30 | Goran Glodić Anticoagulation treatment in lung cancer |
| 17:30 – 17:45 | Ana Bačelić Gabelica Tumor related cachexia |
| 20:00 | GET TOGETHER |
| NSCLC with molecular alterations Chairpersons: Ivana Canjko, Davorin Radosavljević | |
| 09:00 – 09:15 | Vide Popović How to tailor second line treatment in ALK positive patients? |
| 09:15 – 09:30 | Urška Janžić Upfront treatment of EGFR positive NSCLC |
| 09:30 – 09:45 | Jasna Radić The role of immunotherapy in patients with molecular alterations |
| 09:45 – 10:00 | Katja Mohorčić Treatment of KRAS positive lung cancer – challenges and pitfalls |
| 10:00 – 10:15 | Marko Jakopović Are there any new potential targets besides ‘common’ rare mutations |
| 10:15– 10:45 | Satellite symposium MSD Mir Ali Reza Hoda Synergy of Surgery & Science: Optimising the Outcomes in resectable NSCLC |
| 10:45 – 11:15 | Coffee break |
  NSCLC without molecular alterations Chairpersons: Jasna Radić, Fran Seiwerth | |
| 11:15 – 11:30 | Fran Seiwerth Mechanisms of resistance to immunotherapy |
| 11:30 – 11:45 | Sanja Pleština Do we need immunotherapy in later lines of treatment? |
| 11:45 – 12:00 | Marko Jakopović How to treat NSCLC patients with high PD-L1 expression |
| 12:00 – 12:15 | Dragan Trivanović Can we predict who are long term responders to immunotherapy? |
 Small cell lung cancer Chairpersons: Marko Jakopović, Dražena Srdić | |
| 12:15 – 12:30 | Ivana Canjko Treatment of early-stage SCLC advanced SCLC |
| 12:30 – 12:45 | Dražena Srdić Recent advances in systemic treatment of SCLC |
| Special considerations Chairpersons: Marko Jakopović, Dražena Srdić | |
| 12:45 – 13:00 | Jasna Špiček Macan Anesthesiologic assessment before lung cancer surgery |
| 13:00 – 13:15 | Lidija Ljubičić Oligometastatic disease – is there a correct number? |
| 13:15 | Conclusion remarks |
| 11:30 – 11:45 | Sandra Karabatić The Role of The Clinical Nurse Specialist in Lung Cancer |
| 11:45 – 12:30 | Moderators: Jasminka Miličević, Anela Muratović, Petra Popović, Dijana Sunara, Sandra Karabatić Documentation and Standardization of Care in Oncology Patients |
| 12:30 – 13:00 | Satellite symposium AstraZeneca Filip Popović, Sandra Karabatić Nurse – A vital link in oncology care |